The prognosis of RA has improved over the last decades, due to its prompt recognition, the systematic introduction of disease modifying antirheumatic drugs (DMARDs) at an early stage of the disease, the use of DMARD combinations and the availability of more effective antirheumatic agents.
(1-4)
The development of biologic agents, in particular inhibitors of the tumour necrosis factor (anti-TNF) during the last decade, represents a major breakthrough for the treatment of severe forms of RA (5) (6) (7) (8) . As it is the case for most active therapies, highly effective interventions raise concerns about adverse effects. Controversial data have been published on increased rates of bacterial infections and malignancies associated with anti-TNF agents (9) (10) (11) (12) (13) . Available anti-TNF agents neutralize the TNF in different ways: etanercept (ETA) (Enbrel®, Amgen Inc., Thousand Oaks, CA) is a soluble TNF receptor (humanized protein) acting as a competitive inhibitor, while infliximab (INF) (Remicade®, Centocor INC., Malvern, PA) or adalimumab (ADA) (Humira®, Abbott Laboratories, Illinois, USA) are monoclonal antibodies (chimeric (human IgGк / mouse Fυ) for INF and fully human for ADA) (14, 15) . Given these differences, distinct safety profiles and efficacy figures might be expected between these agents. Post marketing data have indeed suggested an increased risk of reactivation of latent tuberculosis with monoclonal antibodies compared to soluble receptors (16) and suggested that certain anti-TNF agents work better in specific chronic inflammatory diseases than others (17, 18). However, it remains unclear how the differences affect these agents' long-term therapeutic effectiveness and their overall tolerability.
In clinical practice, drug-related side effects, primary non-response or secondary drug resistance to anti-TNF agents are common problems (4, 19) . Comparative analyses of anti-TNF discontinuation rates have generally found no difference between available agents (4) . However, comparative studies are sparse, have limited follow-up time and relatively low numbers of treatment interruptions.
The aims of this population-based cohort study are thus 1) to compare the treatment retention rates between ETA, INF and ADA and 2) to compare the specific causes of treatment discontinuation.
METHODS AND PATIENTS
Study Population: This is a longitudinal, observational, population-based cohort study based on the Swiss RA registry (SCQM-RA, Swiss Clinical Quality Management for Rheumatoid Arthritis). SCQM-RA is a national program designed by the Swiss Society for Rheumatology aiming at following longitudinally patients with RA. Patients are assessed at least yearly for disease activity, radiographic joint damage, function, quality of life and other patient characteristics. Information on current treatment, changes in medication, withdrawal and side effects are also reported. An estimated 70-80% of all RA patients on biologic agents of Switzerland are included in the registry (4) . Approximately half of the patients come from private rheumatology practices, 30 % from non-academic hospital centres and 20% from academic centres. We included all patients of the database treated with an anti-TNF agent between January 1997 and December 2006. When the reason for anti-TNF discontinuation was unclear or the dates of initiation or discontinuation uncertain in the database, we contacted the treating physician to ascertain this information. If he or she did not answer the first mail, a second was sent. Currently, no compelling guidelines or administrative restrictions exist in Switzerland, which would favour the use of one anti-TNF agent over another or limit dose adjustments of these agents, if needed. A study previously published in the same population demonstrated a clinically significant dose escalation for INF (4).
Primary outcome:
The primary endpoints of this study were the time to anti-TNF discontinuation and the specific causes for drug discontinuation. We first examined the time until drug discontinuation independently of the reason that led to drug interruption. Drug discontinuation rates or 'drug survival rates' indicate both the patients' and doctors' satisfaction with the therapy and provide a useful summary measure of the overall treatment effectiveness and tolerability (20, 21) . Drug interruption was defined as the discontinuation of the current anti-TNF agent for more then 6 months. Temporary interruptions (less than 6 months) were not considered a drug discontinuation. We categorized causes of drug discontinuation into adverse events (AEs) (acute systemic reaction including acute infusion or systemic allergic reactions, dermatologic reactions, infectious complications, malignancies and other miscellaneous reasons) and 'non-toxic causes' (including treatment ineffectiveness, patient preferences, pregnancy wish and remission). Adverse events and other causes of treatment interruptions were attributed to the current anti-TNF agent, independently to the previous biologic agent. In order to minimize reporting bias by physicians, we chose a priori to consider only AEs severe enough to cause treatment discontinuation. Physicians were allowed to cite more than one reason for interrupting the anti-TNF agent. Confounding was a concern in this analysis, because the choice of an anti-TNF could be associated with disease severity or treatment tolerability. Because such an association would substantially influence drug discontinuation and the incidence of AEs, we used multivariate adjustments to correct for such confounding effects. The time to discontinuation of anti-TNF agents was analyzed using a Cox proportional hazards model (22) . We then analyzed the proportion of treatment discontinuations explained by specific causes. We first examined the numbers of events by anti-TNF agent and evaluated the statistical significance of differences in proportions using the Pearson's Chi-square test or the Fisher exact test, when adequate (unadjusted analysis). We then analyzed the time to event using Cox proportional hazards model and adjusted for potential confounders (adjusted analysis). Survival curves of the time to discontinuation ('drug survival') or time to event were produced with the Kaplan-Meier productlimit method (22) .
Exposure of interest:
We identified a priori sex, age, disease duration, baseline disease activity, (DAS28 score), baseline functional disability (HAQ score), presence of rheumatoid factor (RF), concomitant Pair-wise comparisons between the 3 treatment groups were planned a priori, but were considered only if the overall comparison indicated a significant difference (ANOVA, p < 0.05).
To maintain a Type I error at 5%, pair-wise comparisons and confidence intervals of therapeutic groups were corrected with Bonferroni's adjustment procedure.
RESULTS
The total person time on anti-TNF agents was 3867 patient-years. Of the 2364 anti-TNF treatment courses 78% were on a first course; 882 patients received ADA, 887 ETA, and 595 INF. The baseline characteristics were consistent between the three anti-TNF groups (table   1) Of note, physicians could motivate anti-TNF discontinuation by more than one reason, explaining why the total exceeds 100%.
The proportion of overall AEs causing treatment discontinuation did not differ significantly between the three anti-TNFs (p=0.093, table 2), although slightly more AEs were reported as cause for treatment discontinuation with INF (52%) compared to the other two agents (~43 and 49%). Similar results were seen when taking into account the time to AE and adjusting for differences in baseline risk factors (table 3) 
DISCUSSION
This study demonstrates a statistically significant difference in discontinuation rates between the three anti-TNF agents, with shorter drug retention, and an increased risk of AEs in patients treated with INF, mainly due to a higher risk of infusion and systemic allergic reactions. Other discontinuation causes were equally distributed across the three anti-TNF agents. Analyses from the British Biologic Register also suggested a higher discontinuation rate of INF (42%) compared to ADA (30%) and ETA (29%) during a first course of anti-TNF (23). Bocqu et al. also found better retention rates with ETA (p=0.0001) and ADA (p=0.01) than with INF at one year (24) .
Similarly, Kristenson et al. suggested a difference of anti-TNF retention at five years between ETA (65%) and INF (36%) (p<0.001) when combined with MTX (25) . However, other analyses, found similar retention rates of available anti-TNF agents in RA (26, 27) . The small number of patients included in these studies probably explains part of these discrepancies. In the literature, anti-TNF treatment survival was shown to be prolonged when combined with MTX (25, 28).
Although we found a trend in favour of a lower risk of anti-TNF discontinuation for anti-TNFs in combination with MTX (HR 0.85 [95% CI 0.70-1.02]), this result did not reach statistical significance (p=0.08). In addition, we observed that a relevant predictor of treatment interruption was the absence of concomitant use of glucocorticoid (HR 1.69 [95% CI 1.46-1.95]). While a decreased risk of infusion reactions with low dose glucocorticoids has been described in patients receiving INF (29) , a potential increase of anti-TNF maintenance by low-dose glucocorticoids is of practical importance but needs to be confirmed in other patient populations.
The most frequent single cause for anti-TNF discontinuation in our study was treatment inefficacy, which was not significantly different between the three anti-TNF agents. Which of treatment ineffectiveness or overall AEs is the primary cause of anti-TNF discontinuation remains of debate in the literature (23, 26, 30, 31) . Moreover, we noted that drug survival was inversely proportional to previous anti-TNF failure and later year of treatment initiation. The inverse association with calendar year of treatment initiation reflects the greater availability of therapeutic alternatives favouring treatment switches over time and the increasing proportion of patients starting biologics after having failed previous anti-TNF agents (4). Switching once anti-TNF (from a soluble receptor to a monoclonal antibody or vice versa) is supported by the literature (23, (32) (33) (34) , but switching a second time seems much less effective (32) , which is demonstrated in our study by very short treatment retention with a third anti-TNF agent (median retention time of only 13 months (IQR 6-29)).
INF was associated with a higher discontinuation rate due to AEs (HR 1.4 [99% CI 1.003-1.96]) compared to ADA and ETA, which was mainly due to an increased incidence of acute systemic reactions (HR 2.15 [99% CI 1. 24-3.7] ). No difference between anti-TNF agents was reported with regards to infections, malignancies and dermatological complications. Furthermore, no differences were found in the incidence of other non-toxic causes of treatment discontinuation (remission, pregnancy (wish) and patient preference). Baseline characteristics between anti-TNF agents were fairly similar and do not explain the difference in drug discontinuation or incidence of AEs. Overall, these results suggest that available anti-TNF agents do not differ in their effectiveness to control RA, but may differ in their incidence of specific AEs. In particular, acute systemic reactions caused more often treatment interruption with INF, which could be related to the structure (chimeric component) and the IV administration of INF.
In the literature, the risk of acute infusion reactions with INF varies considerably (between 0.8 to (42) . Because ETA and ADA are administered subcutaneously, allergic reactions to these two agents are more likely to be categorized as 'dermatological reaction' by treating physicians, which could have created some misclassification. In a sensitivity analysis, we combined the dermatological and acute systemic reaction categories, and still found a significant hazard for this combined AE category with INF (HR 1.69 [99% CI 1.05-2.72]), which suggests that overall allergic reactions remain a more common cause of treatment discontinuation for INF.
The risk of infection was similar for the three drugs. The spectrum of infections reported in this study is similar to that found in literature (respiratory tract, skin and soft tissue, bone and joint, urinary tract infections), although we did not see an increased incidence of skin and soft tissue infections, as has been suggested by others (11, 43) . A difference in susceptibility to MB infections between the monoclonal antibodies and the soluble receptor has also been described (16) . A recent study demonstrated a HR of 10 [95%CI 1.92-52.61] for the risk of tuberculosis reactivation in patients treated with monoclonal antibodies anti-TNF agents as compared to those receiving ETA (44) . Although the incidence of MB infections was too low in our population to demonstrate significant differences between these agents, we found no MB infections in the ETA group. Furthermore, no significant difference could be demonstrated in solid or lymphomatous tumours between the anti-TNF agents. These findings are similar to those previously published in the literature (27, 45) . The dosages of anti-TNF agents in patients presenting a malignancy were not different from those used in the rest of the study population.
In 19 % of the treatment discontinuations, the specific reason for anti-TNF interruption could not be retrieved, generally due to a lack of response from the physician in charge. We do not think this confounds our results, because missing information is primarily related to the doctor in charge and not to disease characteristics of these patients. Patients missing the specific cause of treatment interruption had similar disease and treatment characteristics than the rest of the population. Since this is an observational study, there is a potential for selection bias between treatment groups. However, the baseline characteristics were relatively homogeneous, but for expected differences (proportion of previous failures to anti-TNF, MTX use). Furthermore, glucocorticoid use is a good proxy for RA disease severity and its prevalence was similar between the 3 treatment groups. The physician's personal preference seemed to be the most involved in the selection of a particular anti-TNF agent. We adjusted the analysis for potential confounders (table 1) ; however we cannot exclude confounding by unmeasured factors. To our knowledge, this is the first cohort study to directly compare the specific causes of treatment discontinuation between the available anti-TNF agents. It is a, population-based study, which minimizes potential selection biases and allowed to adjust the analysis for important confounding factors. The specific causes of treatment discontinuation were reported by the physician in charge of the patient. Inefficacy was the most frequent cause of treatment discontinuation. Definition for inefficacy is ill defined in the literature (46) and remains largely physician -dependant. We did not analyse transitory causes of treatment discontinuation in order to minimize reporting bias, frequent for expected AEs.
This study found a higher discontinuation rate for patients treated with INF than with the other anti-TNF agents. The shorter treatment retention is primarily explained by a higher risk of infusion reactions or acute systemic reactions. Furthermore, with similar rates of treatment discontinuation for inefficacy across all 3 agents, this study suggests no difference in effectiveness between the 3 anti-TNF agents. Given the protective effect of glucocorticoids on infusion reactions with INF (29) , and the longer treatment survival of INF if combination with MTX, our results suggest that ETA or ADA may be considered preferentially for patients unwilling or unable to take MTX or glucocorticoid co-therapy. 
